Aberrant methylation of CDH11 predicts a poor outcome for patients with bladder cancer

Oncology Letters

Volumn 10, Issue 2, 2015, Pages 647-652

  Lin, Ying Li ^a   Gui, Shi Liang ^b   Ma, Jian Guo ^c  

^a XUZHOU CANCER HOSPITAL   (China)

^b JIAMUSI UNIVERSITY   (China)

^c HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Bladder cancer; Cadherin 11; Methylation

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BLADDER CANCER; CDH11 GENE; CHILD; CONTROLLED STUDY; DNA EXTRACTION; DNA METHYLATION; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

EID: 84931310573     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.3337     Document Type: Article

References (28)

1. Ploeg M, Aben KK and Kiemeney LA: The present and future burden of urinary bladder cancer in the world. World J Urol 27: 289-293, 2009.
2. Parkin DM: The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl 42: 12-20, 2008.
3. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
4. Kim WJ, Kim EJ, Jeong P, et al: RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors. Cancer Res 65: 9347-9354, 2005.
5. Kawamoto K, Enokida H, Gotanda T, et al: p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer. Biochem Biophys Res Commun 339: 790-796, 2006.
6. Montgomery JS, Miller DC and Weizer AZ: Quality indicators in the management of bladder cancer. J Natl Compr Canc Netw 11: 492-500, 2013.
7. Shariat SF, Milowsky M and Droller MJ: Bladder cancer in the elderly. Urol Oncol 27: 653-667, 2009.
8. Mueller J, Schrader AJ, Schrader M, Schnoeller T and Jentzmik F: Management of muscle-invasive bladder cancer. Minerva Urol Nefrol 65: 235-248, 2013.
9. Pal SK, Milowsky MI and Plimack ER: Optimizing systemic therapy for bladder cancer. J Natl Compr Canc Netw 11: 793-804, 2013.
10. Kobeissi LH, Yassine IA, Jabbour ME, Moussa MA and Dhaini HR: Urinary bladder cancer risk factors: A Lebanese case-control study. Asian Pac J Cancer Prev 14: 3205-3211, 2013.
11. Ghafouri-Fard S, Nekoohesh L and Motevaseli E: Bladder cancer biomarkers: Review and update. Asian Pac J Cancer Prev 15: 2395-2403, 2014.
12. Ding MX, Wang HF, Wang JS, et al: ppGalNAc T1 as a potential novel marker for human bladder cancer. Asian Pac J Cancer Prev 13: 5653-5657, 2012.
13. Yegin Z, Gunes S and Buyukalpelli R: Hypermethylation of TWIST1 and NID2 in tumor tissues and voided urine in urinary bladder cancer patients. DNA Cell Biol 32: 386-792, 2013.
14. Kim YK and Kim WJ: Epigenetic markers as promising prognosticators for bladder cancer. Int J Urol 16: 17-22, 2009.
15. Kandimalla R, van Tilborg AA and Zwarthoff EC: DNA methylation-based biomarkers in bladder cancer. Nat Rev Urol 10: 327-335, 2013.
16. Deng Z, Niu G, Cai L, Wei R and Zhao X: The prognostic significance of CD44V6, CDH11 and β-catenin expression in patients with osteosarcoma. BioMed Res Int 2013: 496193, 2013.
17. Carmona FJ, Villanueva A, Vidal A, et al: Epigenetic disruption of cadherin-11 in human cancer metastasis. J Pathol 228: 230-240, 2012.
18. Li L, Ying J, Li H, et al: The human cadherin 11 is a pro-apoptotic tumor suppressor modulating cell stemness through Wnt/β-catenin signaling and silenced in common carcinomas. Oncogene 31: 3901-3912, 2012.
19. Nakajima G, Patino-Garcia A, Bruheim S, et al: CDH11 expression is associated with survival in patients with osteosarcoma. Cancer Genomics Proteomics 5: 37-42, 2008.
20. Lin YL, He ZK, Li ZG and Guan TY: Downregulation of CDH13 expression promotes invasiveness of bladder transitional cell carcinoma. Urol Int 90: 225-232, 2013.
21. Lin YL, Liu XQ, Li WP, Sun G and Zhang CT: Promoter methylation of H-cadherin is a potential biomarker in patients with bladder transitional cell carcinoma. Int Urol Nephrol 44: 111-117, 2012.
22. Lin YL, Sun G, Liu XQ, Li WP and Ma JG: Clinical significance of CDH13 promoter methylation in serum samples from patients with bladder transitional cell carcinoma. J Int Med Res 39: 179-186, 2011.
23. Oosterlinck W, Lobel B, Jakse G, et al; European Association of Urology (EAU) Working Group on Oncological Urology: Guidelines on bladder cancer. Eur Urol 41: 105-112, 2002.
24. Greene FL: The American Joint Committee on Cancer: Updating the strategies in cancer staging. Bull Am Coll Surg 87: 13-15, 2002.
25. Babjuk M, Oosterlinck W, Sylvester R, et al; European Association of Urology (EAU): EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59: 997-1008, 2011.
26. Wu Y, Zhang X, Lin L, et al: Aberrant methylation of RASSF2A in tumors and plasma of patients with epithelial ovarian cancer. Asian Pac J Cancer Prev 15: 1171-1176, 2014.
27. Nakajima G, Patino-Garcia A, Bruheim S, et al: CDH11 expression is associated with survival in patients with osteosarcoma. Cancer Genomics Proteomics 5: 37-42, 2008.
28. Kaufman DS, Shipley WU and Feldman AS: Bladder cancer. Lancet 374: 239-249, 2009.